SAN DIEGO, March 22, 2022 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical development in immuno-oncology announced today that it has received clearance from the US Food and Drug Administration to commence Phase I studies with PT199, its next generation monoclonal antibody (mAb) against CD73 in adult patients with advanced solid […]
SAN DIEGO, March 16, 2022 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and development in immuno-oncology, announced today that three posters featuring its IND-enabling stage molecules will be presented at the upcoming 2022 American Association for Cancer Research (AACR 2022) Annual Meeting, which will be held April 8-13, 2022, in New Orleans, LA. […]
SAN DIEGO, Feb. 4, 2022 Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and development in immuno-oncology announced today that the company has been granted a patent (Patent No. US11,214,615) by the United States Patent and Trademark Office (USPTO). Phanes has been focusing on innovative drug discovery and early development in immuno-oncology and […]
SAN DIEGO, Jan. 11, 2022 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research in immuno-oncology announced today that it has appointed Mr. Paul Chu, MBA, as Vice President of Business Development. “We welcome Paul to the Phanes family and are delighted to appoint a professional of his caliber as Vice President of Business Development,” […]
SAN DIEGO, Dec. 15, 2021 /PRNewswire/ — Phanes Therapeutics, Inc., an emerging biotech company focused on innovative drug discovery and development in immuno-oncology, today announced that it has scheduled a company presentation at Biotech Showcase™ 2022, to be held January 10–12, during the most important week in healthcare at the Hilton San Francisco Union Square. Dr. Ming Wang, CEO, […]
SAN DIEGO, Sept. 10, 2021 Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative drug discovery research and development in immuno-oncology announced today that it has developed a proprietary technology platform, SPECpair™, which enables the use of the conventional monoclonal antibody (mAb) manufacturing process in the production of native IgG-like bispecific antibodies. This is the third […]
SAN DIEGO and SHANGHAI, May 25, 2021 Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative drug discovery in immuno-oncology, announced today the completion of $40 million Series B financing. The round of financing was led by Sequoia Capital China with participation from new investors and current shareholders. The proceeds from this round will be […]
SAN DIEGO, June 16, 2020 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research in immuno-oncology announced today that it has developed a proprietary bispecific antibody technology platform, PACbody™, which enables construction of a bispecific antibody using any pair of monoclonal antibodies (mAbs) while maintaining the IgG-like structure. The technology was […]
San Diego, California/December 12, 2019 – Phanes Therapeutics, Inc., an emerging biotech company focused on innovative drug discovery in immuno-oncology, today announced that it has scheduled a company presentation at Biotech Showcase™ 2020, to be held January 13–15, during the most important week in healthcare at the Hilton San Francisco Union Square. Dr. Ming Wang, […]
Phanes Therapeutics and Phanes Biopharmaceuticals (“Phanes”) recently formed an important strategic alliance with Fosun Kite Biotechnology (“Fosun Kite”). Under the alliance agreement, Phanes will exclusively provide Fosun Kite a collection of all high-affinity humanized antibodies targeting two novel cancer antigens for the development and commercialization of innovative CAR-T products for solid tumor treatments in China […]
